Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration

Abstract This was a prospective, single‐dose, single‐arm, open‐label, non‐randomized, multicenter clinical study to determine cardiovascular safety after a single brolucizumab 6 mg intravitreal injection in neovascular age‐related macular degeneration patients (N = 14). Electrocardiogram (ECG) data...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Melissa Liew, Margarita Gekkieva, Markus Hinder
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2022-04-01
Colecção:Pharmacology Research & Perspectives
Assuntos:
anti‐VEGF
brolucizumab
cardiovascular
intravitreal
nAMD
Acesso em linha:https://doi.org/10.1002/prp2.897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados